Acquired by Amgen (NASDAQ:AMGN) in Oct 2022
CCXI - ChemoCentryx, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Carlos,
United States
Type: Equity
CCXI price evolution
CCXI
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $44.4 | $40.58 | $49.98 | $93.73 |
| Short term investments | $284.22 | $300.02 | $214.51 | $175.7 |
| Net receivables | $4.95 | $2.81 | $0.45 | $20.06 |
| Inventory | $5.47 | $2.9 | $0.85 | |
| Total current assets | $345.17 | $351.63 | $269.18 | $293.38 |
| Long term investments | $17.55 | $31.23 | $97.86 | $102.03 |
| Property, plant & equipment | $55.22 | $56.07 | $57.08 | $58.04 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $74.22 | $88.82 | $156.47 | $161.46 |
| Total investments | $301.77 | $331.26 | $312.37 | $277.73 |
| Total assets | $419.39 | $440.45 | $425.65 | $454.85 |
| Current liabilities | ||||
| Accounts payable | $7.59 | $5.42 | $6.75 | $4.41 |
| Deferred revenue | $78.32 | $80.8 | $35.77 | $37.04 |
| Short long term debt | $19.72 | $19.13 | $18.92 | $14.01 |
| Total current liabilities | $76.08 | $68.81 | $63.02 | $60.03 |
| Long term debt | $49.25 | $50.62 | $51.55 | $56.23 |
| Total noncurrent liabilities | $106.78 | $112.93 | $76.52 | $78.92 |
| Total debt | $68.97 | $69.74 | $70.47 | $70.25 |
| Total liabilities | $182.86 | $181.73 | $139.53 | $138.95 |
| Shareholders' equity | ||||
| Retained earnings | -$687.36 | -$655.71 | -$617.1 | -$576.57 |
| Other shareholder equity | -$2.31 | -$1.85 | -$0.48 | -$0.04 |
| Total shareholder equity | $236.53 | $258.72 | $286.12 | $315.89 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $49.98 | $32.3 | $39.18 | $28.09 |
| Short term investments | $214.51 | $404.27 | $133.61 | $148.9 |
| Net receivables | $0.45 | $0.17 | $0.18 | $2.06 |
| Inventory | $0.85 | |||
| Total current assets | $269.18 | $441.57 | $174.36 | $181.38 |
| Long term investments | $97.86 | $23.8 | $29.45 | |
| Property, plant & equipment | $57.08 | $52.07 | $3.86 | $1.54 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $156.47 | $77.33 | $34.72 | $1.93 |
| Total investments | $312.37 | $428.07 | $163.06 | $148.9 |
| Total assets | $425.65 | $518.9 | $209.08 | $183.31 |
| Current liabilities | ||||
| Accounts payable | $6.75 | $12.88 | $1.53 | $0.97 |
| Deferred revenue | $35.77 | $36.59 | $100.84 | $134.56 |
| Short long term debt | $18.92 | $6.3 | ||
| Total current liabilities | $63.02 | $51.56 | $59.08 | $64.4 |
| Long term debt | $51.55 | $56.77 | $19.79 | $19.69 |
| Total noncurrent liabilities | $76.52 | $81.73 | $84 | $104.18 |
| Total debt | $70.47 | $63.07 | $19.79 | $19.69 |
| Total liabilities | $139.53 | $133.29 | $143.08 | $168.57 |
| Shareholders' equity | ||||
| Retained earnings | -$617.1 | -$485.34 | -$429.99 | -$374.5 |
| Other shareholder equity | -$0.48 | $0.11 | $0.32 | -$0.2 |
| Total shareholder equity | $286.12 | $385.61 | $66 | $14.74 |
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $11.76 | $5.46 | $2.31 | $17.74 |
| Cost of revenue | $0.8 | $0.2 | $0.3 | |
| Gross Profit | $10.96 | $5.25 | $2.01 | $17.74 |
| Operating activities | ||||
| Research & development | $14.36 | $17.48 | $18.77 | $19.95 |
| Selling, general & administrative | $28.18 | $26.01 | $23.29 | $19.6 |
| Total operating expenses | $42.53 | $43.49 | $42.06 | $39.55 |
| Operating income | -$31.57 | -$38.23 | -$40.05 | -$21.8 |
| Income from continuing operations | ||||
| EBIT | -$31.07 | -$38.01 | -$39.88 | -$21.64 |
| Income tax expense | ||||
| Interest expense | $0.59 | $0.6 | $0.64 | $0.67 |
| Net income | ||||
| Net income | -$31.65 | -$38.61 | -$40.53 | -$22.31 |
| Income (for common shares) | -$31.65 | -$38.61 | -$40.53 | -$22.31 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $32.22 | $64.89 | $36.13 | $42.88 |
| Cost of revenue | $0.3 | |||
| Gross Profit | $31.92 | $64.89 | $36.13 | $42.88 |
| Operating activities | ||||
| Research & development | $82.99 | $77.88 | $70.28 | $62.74 |
| Selling, general & administrative | $78.85 | $42.19 | $24.16 | $20.41 |
| Total operating expenses | $161.84 | $120.07 | $94.43 | $83.14 |
| Operating income | -$129.92 | -$55.18 | -$58.3 | -$40.27 |
| Income from continuing operations | ||||
| EBIT | -$129.06 | -$52.71 | -$53.34 | -$36.74 |
| Income tax expense | ||||
| Interest expense | $2.69 | $2.64 | $2.15 | $1.22 |
| Net income | ||||
| Net income | -$131.75 | -$55.36 | -$55.49 | -$37.97 |
| Income (for common shares) | -$131.75 | -$55.36 | -$55.49 | -$37.97 |
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Net income | -$31.65 | -$38.61 | -$40.53 | -$22.31 |
| Operating activities | ||||
| Depreciation | $1.26 | $1.23 | $1.22 | $1.21 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $8.13 | $9.43 | $7.49 | $7.42 |
| Total cash flows from operations | -$26.13 | $8.83 | -$10.89 | -$25.32 |
| Investing activities | ||||
| Capital expenditures | -$0.4 | -$0.22 | -$0.49 | -$4.35 |
| Investments | $28.48 | -$21.11 | -$36.05 | $46.68 |
| Total cash flows from investing | $28.08 | -$21.34 | -$36.54 | $42.33 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.86 | $6.23 | $3.68 | $0.56 |
| Net borrowings | -$1.05 | |||
| Total cash flows from financing | $1.86 | $3.1 | $3.68 | -$0.49 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $3.82 | -$9.4 | -$43.75 | $16.52 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$131.75 | -$55.36 | -$55.49 | -$37.97 |
| Operating activities | ||||
| Depreciation | $4.72 | $2.77 | $1.64 | $0.51 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $30.69 | $22.91 | $11.64 | $10.83 |
| Total cash flows from operations | -$75.62 | -$81.14 | -$70.12 | $16.44 |
| Investing activities | ||||
| Capital expenditures | -$19.02 | -$15.41 | -$0.79 | -$0.84 |
| Investments | $111.24 | -$266.95 | -$11.74 | -$52.23 |
| Total cash flows from investing | $92.22 | -$282.36 | -$12.53 | -$53.07 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $7.41 | $355.97 | $96.13 | $10.47 |
| Net borrowings | -$1.05 | $4.36 | $14.91 | |
| Total cash flows from financing | $1.08 | $356.62 | $94.82 | $24.7 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $17.68 | -$6.88 | $12.17 | -$11.93 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 71.34M |
| Revenue | $37.28M |
|---|---|
| EBITDA | -$125.67M |
| EBIT | -$130.60M |
| Net Income | -$133.09M |
| Revenue Q/Q | 548.81% |
| Revenue Y/Y | 72.52% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 3.35 |
| Cash/Share | 0.62 |
| EPS | -$1.87 |
|---|---|
| ROA | -30.59% |
| ROE | -48.52% |
| Debt/Equity | 0.49 |
|---|---|
| Net debt/EBITDA | -1.10 |
| Current ratio | 4.54 |
| Quick ratio | 4.47 |